Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study

Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 1...

Full description

Saved in:
Bibliographic Details
Published in:Drug safety Vol. 45; no. 6; pp. 685 - 698
Main Authors: Shoaibi, Azza, Rao, Gowtham A., Voss, Erica A., Ostropolets, Anna, Mayer, Miguel Angel, Ramírez-Anguita, Juan Manuel, Maljković, Filip, Carević, Biljana, Horban, Scott, Morales, Daniel R., Duarte-Salles, Talita, Fraboulet, Clement, Le Carrour, Tanguy, Denaxas, Spiros, Papez, Vaclav, John, Luis H., Rijneek, Peter R., Minty, Evan, Alshammari, Thamir M., Makadia, Rupa, Blacketer, Clair, DeFalco, Frank, Sena, Anthony G., Suchard, Marc A., Prieto-Alhambra, Daniel, Ryan, Patrick B.
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-06-2022
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. Methods We conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Results Overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Conclusion Our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date.
AbstractList Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. Methods We conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Results Overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Conclusion Our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date.
Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. Objectives In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. Methods We conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Results Overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Conclusion Our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date.
Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19) vaccines. In this study, we explored the pre-pandemic co-occurrence of thrombosis with thrombocytopenia (TWT) using 17 observational health data sources across the world. We applied multiple TWT definitions, estimated the background rate of TWT, characterized TWT patients, and explored the makeup of thrombosis types among TWT patients. We conducted an international network retrospective cohort study using electronic health records and insurance claims data, estimating background rates of TWT amongst persons observed from 2017 to 2019. Following the principles of existing VITT clinical definitions, TWT was defined as patients with a diagnosis of embolic or thrombotic arterial or venous events and a diagnosis or measurement of thrombocytopenia within 7 days. Six TWT phenotypes were considered, which varied in the approach taken in defining thrombosis and thrombocytopenia in real world data. Overall TWT incidence rates ranged from 1.62 to 150.65 per 100,000 person-years. Substantial heterogeneity exists across data sources and by age, sex, and alternative TWT phenotypes. TWT patients were likely to be men of older age with various comorbidities. Among the thrombosis types, arterial thrombotic events were the most common. Our findings suggest that identifying VITT in observational data presents a substantial challenge, as implementing VITT case definitions based on the co-occurrence of TWT results in large and heterogeneous incidence rate and in a cohort of patints with baseline characteristics that are inconsistent with the VITT cases reported to date.
Author Mayer, Miguel Angel
Duarte-Salles, Talita
Maljković, Filip
Morales, Daniel R.
DeFalco, Frank
Voss, Erica A.
Rijneek, Peter R.
Minty, Evan
Makadia, Rupa
Ryan, Patrick B.
John, Luis H.
Fraboulet, Clement
Alshammari, Thamir M.
Prieto-Alhambra, Daniel
Ostropolets, Anna
Carević, Biljana
Suchard, Marc A.
Blacketer, Clair
Le Carrour, Tanguy
Shoaibi, Azza
Ramírez-Anguita, Juan Manuel
Horban, Scott
Papez, Vaclav
Denaxas, Spiros
Rao, Gowtham A.
Sena, Anthony G.
Author_xml – sequence: 1
  givenname: Azza
  orcidid: 0000-0002-6976-2594
  surname: Shoaibi
  fullname: Shoaibi, Azza
  email: ashoaibi@its.jnj.com
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 2
  givenname: Gowtham A.
  surname: Rao
  fullname: Rao, Gowtham A.
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 3
  givenname: Erica A.
  surname: Voss
  fullname: Voss, Erica A.
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 4
  givenname: Anna
  surname: Ostropolets
  fullname: Ostropolets, Anna
  organization: Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, Department of Biomedical Informatics, Columbia University Medical Center
– sequence: 5
  givenname: Miguel Angel
  surname: Mayer
  fullname: Mayer, Miguel Angel
  organization: Hospital del Mar Medical Research Institute (IMIM)
– sequence: 6
  givenname: Juan Manuel
  surname: Ramírez-Anguita
  fullname: Ramírez-Anguita, Juan Manuel
  organization: Hospital del Mar Medical Research Institute (IMIM)
– sequence: 7
  givenname: Filip
  surname: Maljković
  fullname: Maljković, Filip
  organization: Heliant Ltd
– sequence: 8
  givenname: Biljana
  surname: Carević
  fullname: Carević, Biljana
  organization: Department of Hospital Epidemiology, University Clinical Center of Serbia
– sequence: 9
  givenname: Scott
  surname: Horban
  fullname: Horban, Scott
  organization: Health Informatics Centre (HIC), University of Dundee
– sequence: 10
  givenname: Daniel R.
  surname: Morales
  fullname: Morales, Daniel R.
  organization: Health Informatics Centre (HIC), University of Dundee
– sequence: 11
  givenname: Talita
  surname: Duarte-Salles
  fullname: Duarte-Salles, Talita
  organization: Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
– sequence: 12
  givenname: Clement
  surname: Fraboulet
  fullname: Fraboulet, Clement
  organization: Assistance Publique - Hôpitaux de Marseille
– sequence: 13
  givenname: Tanguy
  surname: Le Carrour
  fullname: Le Carrour, Tanguy
  organization: Easter-eggs
– sequence: 14
  givenname: Spiros
  surname: Denaxas
  fullname: Denaxas, Spiros
  organization: University College London, Institute of Health Informatics
– sequence: 15
  givenname: Vaclav
  surname: Papez
  fullname: Papez, Vaclav
  organization: University College London, Institute of Health Informatics
– sequence: 16
  givenname: Luis H.
  surname: John
  fullname: John, Luis H.
  organization: Department of Medical Informatics, Erasmus University Medical Center
– sequence: 17
  givenname: Peter R.
  surname: Rijneek
  fullname: Rijneek, Peter R.
  organization: Department of Medical Informatics, Erasmus University Medical Center
– sequence: 18
  givenname: Evan
  surname: Minty
  fullname: Minty, Evan
  organization: Departmnet of Biomedical Data Sciences, Stanford University
– sequence: 19
  givenname: Thamir M.
  surname: Alshammari
  fullname: Alshammari, Thamir M.
  organization: Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, Collage of pharmacy, Riyadh Elm University
– sequence: 20
  givenname: Rupa
  surname: Makadia
  fullname: Makadia, Rupa
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 21
  givenname: Clair
  surname: Blacketer
  fullname: Blacketer, Clair
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 22
  givenname: Frank
  surname: DeFalco
  fullname: DeFalco, Frank
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 23
  givenname: Anthony G.
  surname: Sena
  fullname: Sena, Anthony G.
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
– sequence: 24
  givenname: Marc A.
  surname: Suchard
  fullname: Suchard, Marc A.
  organization: Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators, Departments of Biomathematics and Human Genetics, David Geffen School of Medicine, University of California
– sequence: 25
  givenname: Daniel
  surname: Prieto-Alhambra
  fullname: Prieto-Alhambra, Daniel
  organization: Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford
– sequence: 26
  givenname: Patrick B.
  surname: Ryan
  fullname: Ryan, Patrick B.
  organization: Janssen Research & Development, LLC, Observational Health Data Sciences and Informatics (OHDSI), OHDSI Collaborators
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35653017$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1DAUhi1URKeFF2CBLLE2-JLECQuk0XAbqVwEBZaW48vEJWMPtgMKT8RjYpq2wIaVrfP_5zv2-U_AkQ_eAHCf4EcEY_44VZg2FcKUIkxIy9F8C6wI4R0iXUWPwKpUK1R3pDkGJyldYIxb2rR3wDGrm5phwlfg57vB-JDng4HrcReiy8M-QRsizIOBW218dtYpmV3wUHoNN4OMUmUT3Y-lGCz8JJVy3qCt15MyGp4PMez7kJ26vqo5h4PxTkLn4XsjR_g5xFHDZzLLJ3ANX09jdv4SWLQ3Jn8P8QvchCHEDD_kSc93wW0rx2TuXZ2n4OOL5-ebV-js7cvtZn2GVMWrjKq6UsxQaa3htdQ95aTrMVdNp6xkvek0Y13XS46l1a22TDOtONUtthzrvman4OnCPUz93mhVFhDlKA7R7WWcRZBO_Kt4N4hd-CbKmnFb4wJ4eAWI4etkUhYXYYrlW0nQhrc14TXviosuLhVDStHYmwkEi9_piiVdUdIVl-mKuTQ9-PttNy3XcRYDWwypSH5n4p_Z_8H-AnUwuIc
CitedBy_id crossref_primary_10_1093_jamia_ocac203
crossref_primary_10_1038_s41541_022_00569_8
crossref_primary_10_1016_j_eclinm_2023_101932
crossref_primary_10_3389_fphar_2023_1118203
crossref_primary_10_1136_bmj_2022_071594
crossref_primary_10_1016_j_vaccine_2023_07_013
Cites_doi 10.1136/bmj.n1114
10.1055/s-0038-1634402
10.1136/bmj.n1435
10.1016/j.ajem.2021.05.054
10.1016/j.lanepe.2021.100260
10.15585/mmwr.mm7018e2
10.1038/s41598-017-08839-5
10.1016/S0140-6736(21)01693-7
10.1016/j.vaccine.2021.07.013
10.1136/amiajnl-2011-000376
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
Copyright Springer Nature B.V. Jun 2022
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: Copyright Springer Nature B.V. Jun 2022
DBID C6C
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
4T-
7RV
7T2
7TK
7U7
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
C1K
CCPQU
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOI 10.1007/s40264-022-01187-y
DatabaseName SpringerOpen
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Docstoc
Nursing & Allied Health Database (ProQuest)
Health and Safety Science Abstracts (Full archive)
Neurosciences Abstracts
Toxicology Abstracts
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Safety Science Abstracts
ProQuest Medical Library (Alumni)
Toxicology Abstracts
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Docstoc
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1179-1942
EndPage 698
ExternalDocumentID 10_1007_s40264_022_01187_y
35653017
Genre Journal Article
Observational Study
GeographicLocations United Kingdom--UK
United States--US
Europe
Japan
Scotland
Australia
Serbia
Germany
Spain
GeographicLocations_xml – name: Germany
– name: United Kingdom--UK
– name: Australia
– name: Japan
– name: Spain
– name: Serbia
– name: Europe
– name: United States--US
– name: Scotland
GrantInformation_xml – fundername: Innovative Medicines Initiative
  grantid: 806968
  funderid: http://dx.doi.org/10.13039/501100010767
– fundername: NLM NIH HHS
  grantid: R01 LM006910
– fundername: Medical Research Council
  grantid: MC_PC_20059
– fundername: Medical Research Council
  grantid: MC_PC_20051
– fundername: Medical Research Council
  grantid: MR/K006584/1
– fundername: ;
  grantid: 806968
GroupedDBID ---
-EM
04C
0R~
199
29G
2JY
36B
3V.
4.4
406
53G
5GY
5RE
6I2
6PF
7RV
7X7
88E
8FI
8FJ
8R4
8R5
95.
AAAUJ
AADNT
AAFGU
AAIAL
AAIKX
AAJKR
AAKAS
AANZL
AAPBV
AARHV
AATNV
AAWTL
AAYFA
AAYOK
AAYQN
AAYTO
ABDZT
ABFTV
ABIPD
ABJNI
ABJOX
ABKCH
ABKMS
ABKTR
ABLLE
ABMNI
ABOCM
ABPLI
ABPTK
ABTKH
ABTMW
ABUWG
ABWBT
ABXPI
ACBMV
ACBRV
ACBYP
ACCUX
ACGFO
ACGFS
ACIGE
ACMJI
ACMLO
ACOKC
ACPRK
ACREN
ACTTH
ACVWB
ADBBV
ADFRT
ADFZG
ADJJI
ADMDM
ADQRH
ADRFC
ADURQ
ADYOE
ADZCM
ADZKW
AEBTG
AEFTE
AEJHL
AEJOU
AEJRE
AENEX
AEOHA
AEPKY
AEPYU
AESKC
AEVLU
AEXYK
AEYRQ
AFALF
AFKRA
AFNRJ
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGQMX
AHIZS
AHKMG
AHMBA
AHSBF
AIAKS
AILAN
AJDOV
AJRNO
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
ASKOH
ASPBG
AVWKF
AWSVR
AXYYD
AZFZN
A~4
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
C6C
CAG
CCPQU
COF
CS3
DCUDU
DNIVK
DPUIP
DU5
EBLON
EBS
EJD
EMOBN
ESX
EX3
F5P
FERAY
FLLZZ
FNLPD
FSGXE
FYUFA
HMCUK
IAO
IHR
IMOTQ
INH
INR
ITC
IWAJR
J-C
J5H
JZLTJ
L7B
LGEZI
LLZTM
LOTEE
M1P
M4Y
NADUK
NAPCQ
NQJWS
NU0
NXXTH
O9-
OAC
OPC
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
ROL
RSV
RZALA
SISQX
SNPRN
SNX
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
TEORI
TSG
U9L
UAX
UG4
UKHRP
UPIKM
UPOSE
UTJUX
VDBLX
VFIZW
W48
WAF
WOW
YFH
YQY
Z0Y
Z7U
Z7W
Z7X
Z81
Z82
Z83
Z87
ZGI
ZXP
~JE
CGR
CUY
CVF
ECM
EIF
NPM
AACDK
AASML
AAYXX
AAYZH
ABAKF
ABWHX
ACAOD
ACCOQ
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
AIZAD
CITATION
FIGPU
SJYHP
4T-
7T2
7TK
7U7
7XB
8FK
C1K
K9.
PQEST
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c474t-454c3e2affe75adb2719b07c69cfa3be9d3399ba70afd8df3d3dc72d80f70db53
IEDL.DBID AEJHL
ISSN 0114-5916
IngestDate Tue Sep 17 20:47:27 EDT 2024
Thu Oct 10 22:06:40 EDT 2024
Thu Nov 21 23:26:04 EST 2024
Sat Nov 02 12:25:29 EDT 2024
Sat Dec 16 12:08:05 EST 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-454c3e2affe75adb2719b07c69cfa3be9d3399ba70afd8df3d3dc72d80f70db53
ORCID 0000-0002-6976-2594
OpenAccessLink http://link.springer.com/10.1007/s40264-022-01187-y
PMID 35653017
PQID 2678517579
PQPubID 32187
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160850
proquest_journals_2678517579
crossref_primary_10_1007_s40264_022_01187_y
pubmed_primary_35653017
springer_journals_10_1007_s40264_022_01187_y
PublicationCentury 2000
PublicationDate 2022-06-01
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: New Zealand
– name: Auckland
PublicationSubtitle The Official Journal of the International Society of Pharmacovigilance [ISoP]
PublicationTitle Drug safety
PublicationTitleAbbrev Drug Saf
PublicationTitleAlternate Drug Saf
PublicationYear 2022
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References HemminkiKSurveillance bias in cancer risk after unrelated medical conditions: example urolithiasisSci Rep201771141:CAS:528:DC%2BC1MXhvVCrtg%3D%3D10.1038/s41598-017-08839-5
Chen RT, Black S. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS).
AndrewsNJRisk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in EnglandLancet Regional Health-Europe20221310.1016/j.lanepe.2021.100260
Shay DK. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine—United States, March–April 2021. MMWR. Morbidity and Mortality Weekly Report, 2021;70.
SeeICase series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination—United States, December 2020–August 2021medRxiv20213842124
Rao G. CohortDiagnostics. 2020; https://ohdsi.github.io/CohortDiagnostics/. Accessed 11 Apr 2022.
Shimabukuro TT. Update: thrombosis with thrombocytopenia syndrome (tTS) following COVID-19 vaccination. 2021.
LongBBridwellRGottliebMThrombosis with thrombocytopenia syndrome associated with COVID-19 vaccinesAm J Emerg Med202149586110.1016/j.ajem.2021.05.054
Chen RT, Black S. Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). 2021. https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v1.0-1-1.pdf. Accessed 11 Apr 2022.
OverhageJMValidation of a common data model for active safety surveillance researchJ Am Med Inform Assoc2012191546010.1136/amiajnl-2011-000376
Biobank data. https://www.ukbiobank.ac.uk/. Accessed 11 Apr 2022.
LiXCharacterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort studyBMJ2021373n143510.1136/bmj.n1435
BhuyanPVery rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysisLancet2021398103005775781:CAS:528:DC%2BB3MXhs1Oht7%2FL10.1016/S0140-6736(21)01693-7
MacIntyreCRThrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination–A risk–benefit analysis for people< 60 years in AustraliaVaccine20213934478447871:CAS:528:DC%2BB3MXhsF2nu7bE10.1016/j.vaccine.2021.07.013
OHDSI CDM Documentation. GitHub IO. https://github.com/OHDSI/CommonDataModel. Accessed 11 Apr 2022.
VlugAPostmarketing surveillance based on electronic patient records: the IPCI projectMethods Inf Med19993804/053393441:STN:280:DC%2BD3c3msFahug%3D%3D10.1055/s-0038-1634402
JMCD data. https://www.jmdc.co.jp/en/jmdc‐claims‐database. Accessed 11 Apr 2022.
Shimabukuro TT. Thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 vaccine. 2021.
BurnEBackground rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countriesmedRxiv2021384403
PottegårdAArterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort studyBMJ2021373n111410.1136/bmj.n1114
B Long (1187_CR3) 2021; 49
I See (1187_CR5) 2021; 384
1187_CR7
A Vlug (1187_CR10) 1999; 38
1187_CR9
1187_CR4
A Pottegård (1187_CR18) 2021; 373
1187_CR6
JM Overhage (1187_CR8) 2012; 19
1187_CR11
1187_CR1
1187_CR16
CR MacIntyre (1187_CR17) 2021; 39
P Bhuyan (1187_CR2) 2021; 398
K Hemminki (1187_CR20) 2017; 7
1187_CR12
X Li (1187_CR15) 2021; 373
1187_CR14
NJ Andrews (1187_CR19) 2022; 13
E Burn (1187_CR13) 2021; 384
References_xml – volume: 373
  start-page: n1114
  year: 2021
  ident: 1187_CR18
  publication-title: BMJ
  doi: 10.1136/bmj.n1114
  contributor:
    fullname: A Pottegård
– volume: 38
  start-page: 339
  issue: 04/05
  year: 1999
  ident: 1187_CR10
  publication-title: Methods Inf Med
  doi: 10.1055/s-0038-1634402
  contributor:
    fullname: A Vlug
– volume: 373
  start-page: n1435
  year: 2021
  ident: 1187_CR15
  publication-title: BMJ
  doi: 10.1136/bmj.n1435
  contributor:
    fullname: X Li
– volume: 49
  start-page: 58
  year: 2021
  ident: 1187_CR3
  publication-title: Am J Emerg Med
  doi: 10.1016/j.ajem.2021.05.054
  contributor:
    fullname: B Long
– volume: 13
  year: 2022
  ident: 1187_CR19
  publication-title: Lancet Regional Health-Europe
  doi: 10.1016/j.lanepe.2021.100260
  contributor:
    fullname: NJ Andrews
– ident: 1187_CR4
  doi: 10.15585/mmwr.mm7018e2
– volume: 7
  start-page: 1
  issue: 1
  year: 2017
  ident: 1187_CR20
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-08839-5
  contributor:
    fullname: K Hemminki
– volume: 398
  start-page: 577
  issue: 10300
  year: 2021
  ident: 1187_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01693-7
  contributor:
    fullname: P Bhuyan
– volume: 384
  start-page: 403
  year: 2021
  ident: 1187_CR13
  publication-title: medRxiv
  contributor:
    fullname: E Burn
– volume: 39
  start-page: 4784
  issue: 34
  year: 2021
  ident: 1187_CR17
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.07.013
  contributor:
    fullname: CR MacIntyre
– volume: 19
  start-page: 54
  issue: 1
  year: 2012
  ident: 1187_CR8
  publication-title: J Am Med Inform Assoc
  doi: 10.1136/amiajnl-2011-000376
  contributor:
    fullname: JM Overhage
– ident: 1187_CR9
– volume: 384
  start-page: 2124
  year: 2021
  ident: 1187_CR5
  publication-title: medRxiv
  contributor:
    fullname: I See
– ident: 1187_CR14
– ident: 1187_CR16
– ident: 1187_CR1
– ident: 1187_CR12
– ident: 1187_CR11
– ident: 1187_CR6
– ident: 1187_CR7
SSID ssj0008268
ssib024180215
Score 2.4489868
Snippet Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease...
Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease 2019 (COVID-19)...
Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified as a rare but serious adverse event associated with coronavirus disease...
SourceID pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 685
SubjectTerms Algorithms
Biobanks
Cohort analysis
Cohort Studies
Collaboration
Coronaviruses
COVID-19
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Data sources
Diagnosis
Drug Safety and Pharmacovigilance
Electronic health records
Electronic medical records
Hematology
Heterogeneity
Hospitals
Humans
Immunization
Informatics
Information systems
Laboratories
Medicine
Medicine & Public Health
Original
Original Research Article
Pandemics
Patients
Pharmacology/Toxicology
Phenotype
Phenotypes
Primary care
Retrospective Studies
Surveillance
Thrombocytopenia
Thrombocytopenia - chemically induced
Thrombocytopenia - epidemiology
Thromboembolism
Thrombosis
Thrombosis - chemically induced
Thrombosis - etiology
Vaccines
Viral diseases
Title Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study
URI https://link.springer.com/article/10.1007/s40264-022-01187-y
https://www.ncbi.nlm.nih.gov/pubmed/35653017
https://www.proquest.com/docview/2678517579
https://pubmed.ncbi.nlm.nih.gov/PMC9160850
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RVkJIiEJ4uZRqDqgXYuT6kbW5RWmqCNEqgoK4WfskEdRGiXvwP-Jndnb9iNLCAW6RbNkb7eeZb-fxDcAbbtN_cSD90EWr7KeYCTOyw8wMQSTmobEZ3dlndvEtPZ1amZyoD10UP951GUlnqPteNzrojGLfFp-7Edl-vQN75HsSAvfeePph9rGDEfmk1Hqy3iATg3YGmai_nxAdantn_vzUbf90h3TerZ28lUB1fuls_7_-0WN41NJQHDe4eQL3dDGA--dton0Ax_NG0roe4uWmQ2s9xGOcb8Su6wE8bOJ-2LQzPYXf84UuShvYxfHP7-VqWS2u1kjMGIlpYtMWbNo4IfJC4aRXjG4aQrE0-JVLuwzfzhWRWtESVuWVKGkF3U9ZV3bu15LjssBP9G50VUF4yiv-Hsfo-oq7QCdeNLXuOCkXdNpAWztZP4MvZ9PLycxvp0H4MmZxZcXZZaRDboxmCVciZCeZCJgcZdLwSOhMRUS2BGcBNypVJlKRkixUaWBYoEQSPYfdoiz0S8CRSJQ-yTKdGBGHMk2NUERbJLErwnSsPHjbYSD_1Yh-5L28s9u1nHYtd7uW1x4cdjDJWwOwzkMiAQlRM5Z58KJBTP-oiEg02VXmAdvCUn-DlfzevlIsF076m9BrNQY9GHaQ2rzy7ys8-LfbX8GD0KHSxpoOYbdaXevXsLNW10ftp3ZEx47J-Q120yf7
link.rule.ids 230,315,782,786,887,27933,27934,41073,42142,48345,48347,49650,49652,52153
linkProvider Springer Nature
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RVAIkxCNAMRSYA-qFWHL9yNrcoqRVEG0UQUDtydqHl0RqbZS4B_8jfiaz60cUCge4WbLlXWs_z347j28A3nET_gs96frWW2V-xUTooWlmpgkiIfe1iehOv7DZRTw5MTI5YVsLY7Pd25CktdRdsRuddIaha7LPbY9st9qDfaN27vdgf3RxeTlpcUSbUmy2ss4iE4W2Fpm4vxsRH2qKZ_781t0N6hbrvJ08-VsE1W5Mp4_-75Mew8OGiOKoRs4TuJPlfbh73oTa-3A0r0WtqwEutjVamwEe4Xwrd1314UHt-cO6oOkp_Jwvs7wwrl0cXX0v1qtyeb1B4sZIXBPrwmDdeAqR5wrHnWZ0XRKKhcZvXJppuKaziMwUTWFdXIuCZtBeyqo0nb9WHFc5fqax0eYF4YSX_AOO0FYWt65OnNXZ7jgulnTeQJM9WT2Dr6cni_HUbfpBuDJkYWnk2WWQ-VzrjEVcCZ8dJ8JjcphIzQORJSoguiU487hWsdKBCpRkvoo9zTwlouA59PIiz14ADkWksuMkySItQl_GsRaKiIskfkWoDpUD71sQpD9q2Y-0E3i2q5bSqqV21dLKgcMWJ2ljAjapTzQgInLGEgcOash0rwqIRpNlZQ6wHTB1DxjR7907-Wppxb8JvkZl0IFBC6ntkH-f4ct_e_wt3Jsuzs_Ss4-zT6_gvm8RajxPh9Ar1zfZa9jbqJs3zX_3C4VTKzc
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RVqqQEI_wqKHAHFAvxKrrR9bmFuWhACWKoCBu1j68JFJrV4l78D_iZzK7fkShcEDcItmyN9rPu9_OzPcNwBtu0n-hJ13fRqvMp5gIPTDNzDRBJOS-Nhnd2Rc2_x6PJ8Ymp1Px22r3NiVZaxqMS1Nenl4rfdoJ3-jUMwhdU4lu-2W71R4chHSSIaQfDCcfZuctpmiDis221q3ORKft6kznADcibtQIaf781N3N6hYDvV1I-Vs21W5S0wf___cewv2GoOKwRtQjuJPlPTj81KTge3CyqM2uqz5ebLVbmz6e4GJrg1314F4dEcRa6PQYfi6WWV6YkC8OL38U61W5vNogcWYkDoq1YFg3EUTkucJR5yVdS0Wx0PiNSzMM13QckZmiIayLK1HQCNqfsipNR7AVx1WOn-ndaOuFcMxL_g6HaBXHbQgU53UVPI6KJZ1D0FRVVk_g63RyMZq5TZ8IV4YsLI1tuwwyn2udsYgr4bOzRHhMDhKpeSCyRAVEwwRnHtcqVjpQgZLMV7GnmadEFDyF_bzIsyPAgYhUdpYkWaRF6Ms41kIRoZHEuwjtoXLgbQuI9Lq2A0k742c7aynNWmpnLa0cOG4xkzZLwyb1iR5ERNpY4sCzGj7dowKi17TiMgfYDrC6G4wZ-O6VfLW0puAEZeM-6EC_hdf2lX8f4fN_u_01HC7G0_T8_fzjC7jrW4CagNQx7Jfrm-wl7G3UzavmE_wFNWgzuA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phenotype+Algorithms+for+the+Identification+and+Characterization+of+Vaccine-Induced+Thrombotic+Thrombocytopenia+in+Real+World+Data%3A+A+Multinational+Network+Cohort+Study&rft.jtitle=Drug+safety&rft.au=Shoaibi%2C+Azza&rft.au=Rao%2C+Gowtham+A.&rft.au=Voss%2C+Erica+A.&rft.au=Ostropolets%2C+Anna&rft.date=2022-06-01&rft.pub=Springer+International+Publishing&rft.issn=0114-5916&rft.eissn=1179-1942&rft.volume=45&rft.issue=6&rft.spage=685&rft.epage=698&rft_id=info:doi/10.1007%2Fs40264-022-01187-y&rft.externalDocID=10_1007_s40264_022_01187_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0114-5916&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0114-5916&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0114-5916&client=summon